Abstract:These results suggest that IL-17 is an in vitro stimulator of angiogenic factor release, both by its own action and by cooperating with TNF-alpha.
“…Moreover, the levels of Th17 cells were positively correlated with microvessel density in tumors (87). By acting on stromal cells and fibroblasts, IL-17 induces a wide range of angiogenic mediators (88,89), including vascular endothelial growth factor (VEGF), that markedly promote inflammatory and tumor angiogenesis (90). IL-17 is able to up-regulate VEGF production by fibroblasts and therefore promote fibroblast-induced new vessel formation in inflammation and tumors.…”
Section: Regulation Of Th17 Differentiation In Tumorsmentioning
Inflammation appears to be a necessity for both metastasis and elimination of tumor cells. IL-17, a proinflammatory cytokine produced by Th17 cells, contributes to both the processes by playing a dual role in the antitumor immunity. On one hand, IL-17 promotes an antitumor cytotoxic T cell response leading to tumor regression. On the other hand, by facilitating angiogenesis and egress of tumor cells from the primary focus, IL-17 promotes tumor growth. Thus, the therapeutic application that uses IL-17 needs to be refined by minimizing its protumor functions.
“…Moreover, the levels of Th17 cells were positively correlated with microvessel density in tumors (87). By acting on stromal cells and fibroblasts, IL-17 induces a wide range of angiogenic mediators (88,89), including vascular endothelial growth factor (VEGF), that markedly promote inflammatory and tumor angiogenesis (90). IL-17 is able to up-regulate VEGF production by fibroblasts and therefore promote fibroblast-induced new vessel formation in inflammation and tumors.…”
Section: Regulation Of Th17 Differentiation In Tumorsmentioning
Inflammation appears to be a necessity for both metastasis and elimination of tumor cells. IL-17, a proinflammatory cytokine produced by Th17 cells, contributes to both the processes by playing a dual role in the antitumor immunity. On one hand, IL-17 promotes an antitumor cytotoxic T cell response leading to tumor regression. On the other hand, by facilitating angiogenesis and egress of tumor cells from the primary focus, IL-17 promotes tumor growth. Thus, the therapeutic application that uses IL-17 needs to be refined by minimizing its protumor functions.
“…8 Since IL-6 and IL-23 are both involved in the IL-23/IL-17 pathway, in the present study we aimed to elucidate the role of IL-17 in cervical cancer. The function of IL-17 is tissue-and contextdependent and includes activation of nuclear factor-kB (NFkB), 9 vascular endothelial growth factor (VEGF) production and angiogenesis, [10][11][12][13][14] stimulation of pro-inflammatory cytokine production, 15 neutrophil recruitment, 16 and formation of epithelial tight junctions. 17 While it is clear that IL-17 plays a prominent role in both the protection of the host from invading extracellular pathogens and the destruction of host tissues in several chronic inflammatory and auto-immune disorders, there is controversy about its role in cancer.…”
“…Heparin-binding EGF (HB-EGF), a potent mitogen and chemotactic factor for smooth muscle cells in the EGF family (14), is expressed mainly in the airway epithelium and is significantly upregulated in asthmatic airways (15). In vitro, there is also evidence that IL-17 can stimulate HB-EGF secretion by synovial fibroblasts (16). These observations led us to investigate the role of the EGFR pathway in Th17-related airway remodeling.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citationsâcitations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.